Angelini Pharma launches LIFE-GREENAPI as part of its green transition strategy, supported with a €1.5M grant from the European Commission
Summary
Angelini Pharma launches LIFE-GREENAPI as part of its green transition strategy, supported with a 1.5M grant from the European Commission - The three-year initiative will be implemented in collaboration with the University of Leiden (The Netherlands) - LIFE-GREENAPI will deploy a more efficient, greener, and innovative process for producing Active Pharmaceutical Ingredients (APIs), by switching from batch to flow chemistry technology Rome (Italy) 13 July 2023 Angelini Pharma, part of the privately owned Angelini Industries, announced today the launch of LIFE-GREENAPI, an initiative designed to develop pharma production practices with low environmental impact. The project is part of a wider business sustainability strategy which Angelini Pharma is undertaking to address the environmental impact of the companys products throughout their entire life cycle. LIFE-GREENAPI represents a core initiative of Angelini Pharmas green transition strategy and I strongly believe this enterprise has the capacity to inspire and encourage the broader pharmaceutical sector in Europe to fully embrace environmental sustainability in its production processes. In close contact with the company, we will work towards a continuous and iterative study of the system, from the lab to the pre-commercial phase, said Stefano Cucurachi, Associate Professor of Industrial Ecology at Leiden University. Located in the industrial outskirts of Aprilia (Southern Rome Area, Italy), with 70,000 m2 cGMP manufacturing facility and cutting-edge R&D labs, this business unit is housing a wide reaction technology portfolio and scale-up capabilities to meet small molecule outsourcing needs of the pharmaceutical industry from Proof-of-Concept to early-stage clinical lots onto cGMP commercial manufacturing, from 1 to 1,000+ kg up to MT scale.